Skip to main content

Table 1 Criteria for evaluation of response of breast lesions and axillary lymph nodes by DCE-MRI versus PET/CT

From: Predicting pathological response of locally advanced breast cancer to neoadjuvant chemotherapy: comparing the performance of whole body 18F-FDG PETCT versus DCE-MRI of the breast

Response category Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
(Eisenhauer et al. 2009) [23]
PET Response Criteria in Solid Tumors (PERCIST)
(Wahl et al. 2009) [24]
Complete response (CR) Disappearance of all target lesions
Reduction in short axis of target lymph nodes to < 10 mm
Disappearance of all lesions on PET images to background blood- pool levels, regardless of % change from baseline and anatomic size
Partial response (PR)  ≥ 30% decrease in sum of target lesion diameter sum  ≥ 30% decrease in sum of target lesion SUV
Progressive disease (PD)  ≥ 20% increase in sum of target lesion diameter and minimum of 5 mm total increase or new lesion 30% increase in sum of target lesion SUV or new FDG avid lesion
  or unequivocal progression of non-target lesions or unequivocal progression of non-target lesion (e.g., ≥ 30% increase) or unequivocal progression by RECIST
Stable disease (SD) Does not meet other criteria Does not meet other criteria
Axillary lymph nodes assessment Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in short axis. At baseline and in follow-up, only the short axis will be measured and followed Follow the same criteria as the breast lesions regarding SUV change (CR, PR, PD and SD)